- Home
- XYL vs RVMD Comparison
XYL vs RVMD Comparison
Compare XYL & RVMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | XYL | RVMD |
|---|---|---|
| Founded | 2011 | 2014 |
| Country | United States | United States |
| Employees | N/A | 883 |
| Industry | Fluid Controls | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 26.0B | 30.1B |
| IPO Year | 2011 | N/A |
Fundamental Metrics
Financial Performance| Metric | XYL | RVMD |
|---|---|---|
| Price | $120.65 | $190.46 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 13 | 19 |
| Target Price | ★ $152.50 | $140.84 |
| AVG Volume (30 Days) | 1.8M | ★ 3.0M |
| Earning Date | 04-28-2026 | 05-06-2026 |
| Dividend Yield | ★ 1.49% | N/A |
| EPS Growth | ★ 7.40 | N/A |
| EPS | ★ 0.79 | N/A |
| Revenue | ★ $9,035,000,000.00 | N/A |
| Revenue This Year | $2.79 | N/A |
| Revenue Next Year | $4.49 | $533.02 |
| P/E Ratio | $150.99 | ★ N/A |
| Revenue Growth | ★ 5.52 | N/A |
| 52 Week Low | $105.29 | $34.00 |
| 52 Week High | $154.27 | $193.69 |
Technical Indicators
Market Signals| Indicator | XYL | RVMD |
|---|---|---|
| Relative Strength Index (RSI) | 67.09 | 73.52 |
| Support Level | $115.88 | $93.39 |
| Resistance Level | $120.49 | N/A |
| Average True Range (ATR) | 2.56 | 7.21 |
| MACD | 0.94 | 1.87 |
| Stochastic Oscillator | 95.49 | 93.53 |
Price Performance
Historical ComparisonAbout XYL Xylem Inc. New
Xylem is a global leader in water technology and offers a wide range of solutions, including the transport, treatment, testing, and efficient use of water for customers in the utility, industrial, commercial, and residential sectors. Xylem was spun off from ITT in 2011. Based in Rye Brook, New York, Xylem has a presence in over 150 countries and employs 16,200. The company generated $9 billion in revenue in 2025.
About RVMD Revolution Medicines Inc.
Revolution Medicines Inc is a clinical-stage precision oncology company developing novel targeted therapies for RAS-addicted cancers. The Company possesses structure-based drug discovery capabilities built upon chemical biology and cancer pharmacology know-how and proprietary technologies that enable the creation of small molecules tailored to unconventional binding sites. Its research and development pipeline comprises inhibitors that bind directly to RAS variants (RAS(ON) Inhibitors), designed to be used as monotherapy, in combination with other RAS(ON) Inhibitors and/or other therapeutic agents.